维持期皮下免疫治疗的循证剂量:当代实践综述
本文综述1980至2016年皮下免疫治疗剂量-反应研究,将推荐剂量转换为5 mL维持瓶应添加的变应原提取液体积。安全有效剂量可能为每次注射主要变应原5-20 μg;多数变应原从含0.2 mL厂商提取液的5 mL瓶注射0.5 mL可达有效范围下限,猫、狗或仅含一种尘螨时需更大体积。
要点
- 皮下免疫治疗安全有效剂量可能为每次注射主要变应原5-20 μg。
- 多数变应原5 mL维持瓶加0.2 mL厂商提取液、注射0.5 mL可达有效范围下限。
- 猫、狗或仅含一种尘螨时需更大体积提取液才能达到有效范围。
核心结论
- 当前耳鼻咽喉过敏实践常从含0.2 mL厂商提取液的5 mL维持瓶注射0.5 mL,除猫、狗外可能提供有效剂量。
- 特定临床情况应考虑增加提取液体积以达到 probable effective dose range 更高水平。
研究设计与样本
- 综述,全面检索1980-2016年EBM数据库、Medline、PreMedline及National Guideline Clearinghouse的剂量-反应研究。
- 将推荐剂量转换为5 mL维持瓶应添加的变应原提取液体积。
主要发现
- 皮下免疫治疗安全有效剂量可能为每次注射主要变应原5-20 μg。
- 含0.2 mL厂商提取液的5 mL维持瓶注射0.5 mL,对多数变应原可达 probable effective dose range 下限。
- 治疗含猫、狗或仅一种尘螨时,需更大体积提取液才能达到该范围。
关键数值与推荐
- 安全有效剂量可能为每次注射主要变应原5-20 μg。
- 多数变应原从含0.2 mL厂商提取液的5 mL维持瓶注射0.5 mL可达有效范围下限。
- 猫、狗或仅一种尘螨需更大体积提取液。
- 每月1或2次注射可能提供有效剂量,除猫、狗外与已发表指南一致。
临床怎么用
- 维持期可按5 mL瓶加0.2 mL厂商提取液、注射0.5 mL执行,但猫、狗或仅一种尘螨时应考虑增加提取液体积。
- 特定临床情况可增加提取液体积以使维持剂量位于 probable effective dose range 更高水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subcutaneous immunotherapy is an effective allergy treatment only if properly dosed. In this article we review the data on the probable effective dose range for subcutaneous immunotherapy and convert the recommended doses into a clinically relevant format. METHODS: A comprehensive literature search of dose-response subcutaneous immunotherapy studies was done of EBM databases, Medline database, PreMedline, and the National Guideline Clearinghouse for the period 1980-2016. Recommended doses were converted to the volume of allergen extract that should be added to a 5-mL maintenance vial. RESULTS: A safe and effective dose for subcutaneous immunotherapy is likely 5-20 μg of major allergen per injection. A 0.5-mL injection from a 5-mL maintenance vial containing 0.2 mL of manufacturer's extract of each allergen should reach the lower end of the probable effective dose range for most allergens. A larger volume of extract is required to reach that range when treatment includes cat, dog, or only 1 dust mite. Increasing beyond the commonly prescribed 0.2 mL of manufacturer's extract added to a 5-mL treatment vial is reasonable for nearly all allergens to achieve a maintenance dose higher in the probable effective dose range. CONCLUSION: Current otolaryngic allergy practice usually escalates patients to 0.5-mL injections from 5-mL maintenance vials containing 0.2 mL of manufacturer's extract of each allergen. With the main exceptions of cat and dog, those injections administered 1 or 2 times per month likely provide an efficacious dose of allergen and are consistent with published guidelines. A larger volume of extract should be considered in certain clinical situations.
引用
- Hoover H, Leatherman B, Ryan M, et al. Evidence-based dosing of maintenance subcutaneous immunotherapy: a contemporary review of state-of-the-art practice. Int Forum Allergy Rhinol. 2018. PMID: 29631326. doi:10.1002/alr.22118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。